Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Canine-human cancer finding could advance new therapies
"This research was a good example of a full cycle of translational research" - Dr Santiago Peralta.

Researchers confirm molecular similarities between oral tumours found in dogs and people.

US researchers have discovered a striking resemblance between a non-lethal canine tumour and a devastating tumour in people, paving the way for new treatments in both veterinary and human medicine.

The study by Cornell University found that canine acanthomatous ameloblastoma (CAA) – a common tumour of dogs – is molecularly similar to a rare oral tumour in humans known as ameloblastoma (AM).

Scientists had previously noted a resemblance between CAA and AM, but it is not until now that any molecular similarities have been confirmed. The findings are published in the journal Scientific Reports.

“This research was a good example of a full cycle of translational research,” commented lead author Dr Santiago Peralta, a veterinary dentist and oral surgeon at the University’s College of Veterinary Medicine. “We took something we were dealing with in the clinical setting, studied it in the bench setting and are now hoping to use it to help veterinary patients and, potentially, humans.”

Previous research by Peralta and his team revealed both AM and CAA shared mutations in a well-known signalling pathway, known as the RAS-RAF-MAPK pathway.  In this study, the team analysed a large genomic dataset generated by the Cornell Transcriptional Regulation and Expression Facility to better understand the biological consequences of these mutations.

At the same time, the team compared the CAA tumours with another common canine tumour (oral squamous cell carcinoma) and healthy gum tissue, made available through the Cornell Veterinary Biobank. The team also used genomic data from human tissues to run comparisons.

Through analysing these different tissues, Peralta and his team were able to see that the mutations they had identified in their earlier study were largely responsible for the tumours they were seeing.
They also found that CAA and AM are very similar at a molecular level - giving strength to the idea that dogs represent a potentially useful natural model of the human tumour.

“All the dysregulated molecules and pathways in CAA tumour tissues were consistent with the mutations we’d found and remarkably similar to those observed in AM,” said Peralta.

The team is now looking to establish in vitro and in vivo models of different canine oral tumours that can be used to test potential drugs. It is hoped that any drugs that prove effective in treating oral tumours in dogs may also have the potential to help human patients.

 

Become a member or log in to add this story to your CPD history

Practices urged to audit neutering data

News Story 1
 RCVS Knowledge has called on vet practices to audit their post-operative neutering outcomes.

It follows the release of the 2024 NASAN benchmarking report, which collates data from neutering procedures performed on dogs, cats and rabbits.

The benchmarking report enables practices in the UK and Ireland to compare their post-operative outcomes to the national average. This includes the rate of patients lost to follow-up, which in 2024 increased to 23 per cent.

Anyone from the practice can submit the data using a free template. The deadline for next report is February 2026.

Visit the RCVS Knowledge website to complete an audit. 

Click here for more...
News Shorts
New guidance for antibiotic use in rabbits

New best practice guidance on the responsible use of antibiotics in rabbits has been published by the BSAVA in collaboration with the Rabbit Welfare Association & Fund (RWA&F).

The guidance is free and has been produced to help veterinary practitioners select the most appropriate antibiotic for rabbits. It covers active substance, dose and route of administration all of which are crucial factors when treating rabbits owing to the risk of enterotoxaemia.

For more information and to access the guide, visit the BSAVALibrary.